OpenAlex
PricingAboutJobs
Log inGet started
Work

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

HTML PDF

Year: 2015
Type: article
Source: Cancer Cell
DOI: 10.1016/j.ccell.2015.08.002
Authors: Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Wei-Ping Lu, Bryan D. Smith, Subha Vogeti, Thomas J. Rutkoski, Scott Wise, Lawrence Chun, Youyan Zhang, Robert D. Van Horn, Tinggui Yin, Xiaoyi Zhang, Vipin Yadav, Shih-Hsun Chen, Xueqian Gong, Xiwen Ma, Yue Webster, Sean Buchanan, Igor Mochalkin, Lysiane Huber, Lisa Kays, Gregory P. Donoho, Jennie Walgren, Denis McCann, Phenil Patel, Ilaria Conti, Gregory D. Plowman, James J. Starling, Daniel L. Flynn
Institutions: Eli Lilly (United States), Deciphera Pharmaceuticals (United States)
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: LY3009120, Raf-1, vemurafenib, dabrafenib, MEK phosphorylation, ERK1/2 phosphorylation, paradoxical activation, KRAS mutation, NRAS mutation, BRAF mutation, anticancer activity, RAF inhibitors
SDG: Good health and well-being

Open Access status: bronze
OpenAlex ID: W1940641879
FWCI: 9.211
Cites: 49
Cited by: 319
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms